Omthera Pharmaceuticals (Bedminster, NJ) a clinical-stage specialty biopharma company focused on an Omega-3 fatty acid containing DHA and EPA as a therapy for dyslipidemia, closed a $33.9M Series B financing. Participants include New Enterprise Associates and Sofinnova Ventures.